Corteria appoints Mark Pruzanski as chairman

Paris, France-based cardiology specialist Corteria Pharmaceuticals has announced the appointment of Dr Mark Pruzanski, as chairman of its board of directors. He replaces Thierry Laugel, managing partner at Kurma Partners, who remains a member of the board.

Dr Pruzanski has more than 30 years of experience as a life sciences executive, entrepreneur and investor. He most recently served as chairman and chief executive of Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of obesity and other cardiometabolic diseases, which was acquired by Eli Lilly (NYSE: LLY) in July 2023.

He also founded Intercept Pharmaceuticals and was the company’s CEO until 2021, having led its evolution from drug discovery stage to a global development and commercial organization with a focus on addressing chronic liver diseases. He serves as a board member of several private and public biotechnology companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security.